Roche (OTCMKTS:RHHBY) Coverage Initiated by Analysts at Morgan Stanley

Equities research analysts at Morgan Stanley began coverage on shares of Roche (OTCMKTS:RHHBY) in a report released on Wednesday,Briefing.com Automated Import reports. The firm set an “equal weight” rating on the stock.

Separately, Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Roche presently has a consensus rating of “Hold”.

Roche Stock Performance

Shares of OTCMKTS RHHBY opened at $39.43 on Wednesday. Roche has a twelve month low of $29.20 and a twelve month high of $42.43. The business’s 50 day moving average price is $36.70 and its two-hundred day moving average price is $38.31. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RHHBY. Brooklyn Investment Group acquired a new stake in Roche during the third quarter worth about $40,000. AlphaMark Advisors LLC acquired a new stake in shares of Roche during the 3rd quarter worth approximately $149,000. IHT Wealth Management LLC bought a new position in Roche in the third quarter valued at approximately $236,000. Verity Asset Management Inc. acquired a new position in Roche during the third quarter valued at approximately $253,000. Finally, Canopy Partners LLC lifted its stake in Roche by 4.6% during the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after purchasing an additional 344 shares during the last quarter.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.